The drug, which is currently priced at $56,000 a year, could surpass $5 billion in annual sales, which will mostly be paid for by Medicare, according to The Wall Street Journal. Though Medicare typically pays for approved medications unconditionally, the government program could restrict access to offset the high costs.
“Medicare can’t afford to treat this as business as usual,” Andy Slavitt, a former Medicare acting administrator and Biden senior adviser, told the Journal.
“Whether or not that drug will be covered by Medicare and Medicaid is an outstanding question, something HHS will have to deal with,” HHS Secretary Xavier Becerra said June 24. “We’re going to be making some pretty heady decisions about how it’s treated, if it will be reimbursed, how much, and so forth.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.